Schedule an Appointment with a Cancer Specialist In-Person or Through a Virtual Visit.
Physicians: Learn About T-Cell Engager Tech Targeting DLL3 To Pursue Unmet Needs In SCLC.
Cancer vaccines help the immune system recognize and eliminate cancer cells. Learn more about cancer vaccines and other forms of immunotherapy here.
A randomized phase II study of a combination of docetaxel and S-1 versus docetaxel monotherapy in patients with non-small cell lung cancer previously treated ...
A Randomized Phase III Study of a Cisplatin (CDDP) and Docetaxel (DOC) with or without Irinotecan (CPT) in Patients with Advanced NSCLC: Okayama Lung Cancer ...
Jun 7, 2010 · The patients were randomly allocated to two groups by the OLCSG Administrative Office (Aichi Cancer Center) according to stratification for the ...
The aim of the present study is to investigate the efficacy and safety of EGFR-TKI readministration with afatinib in patients with advanced NSCLC harboring ...
With this background, the Okayama Lung Cancer Study Group (OLCSG) conducted ... The authors thank all members of the OLCSG for participating in this study.
A randomized phase III trial comparing triple weekly usage with weekly usage of paclitaxel in concurrent chemoradiotherapy for patients with locally advanced ...
People also search for
Related health topics
For informational purposes only. Consult your local medical authority for advice.
... (OLCSG 0501). Date of disclosure of the study information, 2005/09/12 ... (OLCSG 0501). Acronym. Cisplatin and S-1 with radiotherapy for locally ...
IL6発現とEGFR-TKIの効果についての研究 · OLCSG 0102: Phase II study of topotecan and cisplatin for elderly small-cell lung cancer ...
The Okayama Lung Cancer Study Group (OLCSG) 0007 trial with patients up to 75 years showed that with concurrent RT, docetaxel and cisplatin (DP) chemotherapy ...
May 10, 2022 · Pembrolizumab in advanced NSCLC patients with poor performance status and high PD-L1 expression: OLCSG 1801 · Abstract · Introduction · Methods ...